avizakimab   Click here for help

GtoPdb Ligand ID: 12270

Synonyms: BOS 161721 | BOS161721
Compound class: Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
1. Ettinger C, Karnell J, Damschroder M, Chowdhury P, Xiao X, Tsui P, Varkey R, Drabic S, Carter L, Herbst R et al.. (2018)
Antibodies specific for IL-21 and uses thereof.
Patent number: US10022443B2. Assignee: Boston Pharmaceuticals Inc. Priority date: 08/04/2014. Publication date: 17/07/2018.
2. Hussaini A, Mukherjee R, Berdieva DM, Glogowski C, Mountfield R, Ho PTC. (2020)
A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
Clin Transl Sci, 13 (2): 337-344. [PMID:31664766]
3. Long D, Chen Y, Wu H, Zhao M, Lu Q. (2019)
Clinical significance and immunobiology of IL-21 in autoimmunity.
J Autoimmun, 99: 1-14. [PMID:30773373]
4. Satterthwaite AB. (2021)
TLR7 Signaling in Lupus B Cells: New Insights into Synergizing Factors and Downstream Signals.
Curr Rheumatol Rep, 23 (11): 80. [PMID:34817709]
5. Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, Rahman S, Zerrouki K, Hanna R, Morehouse C et al.. (2018)
IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE.
Nat Commun, 9 (1): 1758. [PMID:29717110]